MMRN1 suppresses thyroid cancer progression via activation of the Hippo signaling pathway

Meihua Zhang1, Junjun Guo2, Jun Sun3

  • 1Endoscopy Center, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China.

Endocrine Research
|July 1, 2026
PubMed
Abstract

Insights

Multimerin 1 (MMRN1) suppresses thyroid cancer (TC) by activating the Hippo pathway and influencing oxidative stress and ferroptosis. This discovery presents MMRN1 as a promising therapeutic target for TC treatment.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer (TC) incidence is rising globally, making it the most common endocrine malignancy.
  • The role of Multimerin 1 (MMRN1) in TC is unknown, despite its involvement in other cancers.
  • The Hippo pathway is crucial for regulating cell growth and is often altered in TC.

Purpose of the Study:

  • To investigate the function of MMRN1 in thyroid cancer.
  • To determine if MMRN1 affects the Hippo signaling pathway in TC.
  • To explore MMRN1's impact on oxidative stress and ferroptosis in TC.

Main Methods:

  • Bioinformatics analysis identified differentially expressed genes in TC.
  • MMRN1 expression was confirmed in TC cell lines and normal cells using RT-qPCR and Western blot.
  • Functional assays, Hippo pathway activity assessments, and analysis of oxidative stress/ferroptosis markers were performed.

Main Results:

  • MMRN1 expression was found to be decreased in TC tissues and cell lines.
  • Overexpressing MMRN1 inhibited TC cell proliferation, migration, and invasion, while promoting apoptosis.
  • MMRN1 activated the Hippo pathway and modulated oxidative stress and ferroptosis markers, indicating increased sensitivity to ferroptosis.

Conclusions:

  • MMRN1 functions as a tumor suppressor in thyroid cancer.
  • MMRN1 exerts its effects by activating the Hippo pathway and influencing oxidative stress and ferroptosis.
  • MMRN1 represents a potential therapeutic target for managing thyroid cancer.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...